Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Secret Life of a Cancer-Related Protein Revealed by 3D Structure

Published: Monday, August 12, 2013
Last Updated: Monday, August 12, 2013
Bookmark and Share
Like a fireman who becomes an arsonist, a protein that prevents cells becoming cancerous can also cause tumours.

The finding, published today in Nature Structural and Molecular Biology, stems from the first 3D structure of the protein’s active core, and opens up new avenues for drug design.

“Everybody thought this protein was a tumour-suppressor,” says Daniel Panne, who led the work, “but we’ve found that some mutations make it an oncogene – a gene that turns the cell cancerous – which actually makes it a viable drug target.”

Surprisingly, the finding reveals that mutations to this protein that have been linked to cancer can act in two different ways. As expected, some mutations make this ‘fireman’ protein – known as p300 – unable to put out the fire: they cause it to malfunction and lose control over other genes, thwarting its tumour-suppressor role. But, as Panne and colleagues discovered, some cancer-linked mutations actually make p300 into an arsonist: they make it hyperactive, turning it into an oncogene. Which mutations are which? The secret lies in an unexpected piece of the puzzle.

In this study, Panne and colleagues determined the structure of the whole of the protein’s active core – the part that physically interacts with genetic material to control genes – for the first time. They found that this 3D puzzle had one more piece than expected. p300 has a groove that it uses to slot onto the cell’s genetic material to activate or inactivate genes, and the EMBL scientists found that, sitting on top of that groove like a lid, was a piece no-one knew this protein had. This ‘lid’ is like a built-in self-control mechanism. It determines whether the protein can slot onto genetic material or not: for p300 to do its job, it has to open the lid. But if a mutation interferes with the lid, keeping it permanently open, the protein will go into over-drive, and the resulting uncontrolled gene activity can lead to cancer.

Tumours caused by these hyper-activating mutations could potentially be fought by drugs that inhibit p300. So, armed with the knowledge of the protein’s structure, the EMBL scientists now plan to investigate how to thwart p300 when it goes from fireman to arsonist.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Blocking the Waste Disposal Unit
Detailed structure paves the way for more effective cancer therapies.
Monday, August 08, 2016
Unidentified Spectra Detector
New algorithm clusters over 250 million spectra for analysis, such that millions of unidentified peptide sequences can be recognised.
Friday, July 01, 2016
DNA Protection, Inch by Inch
DNA within reproductive cells is protected through a clever system of find and destroy: new lifts the veil on how this is done.
Monday, July 13, 2015
No Humans Required
Automated tool for tracking proteins and the molecules they interact with in living cells developed.
Wednesday, March 18, 2015
Light at the Ends of the Tunnel
Illuminating the structure of the human nuclear pore complex.
Wednesday, December 11, 2013
Choreographed Origami
Folding ribosomal RNA requires paired tagging sequence.
Monday, October 21, 2013
Cells Keep to One Direction by Erasing the Path
Findings could have implications for cancer and metastasis.
Tuesday, October 01, 2013
Potential New Drug Target for Cystic Fibrosis
Large-scale screen also identified genes not previously linked to the disease.
Friday, September 13, 2013
Catching the Cap-Snatcher
Structural analysis opens the way to new anti-influenza drugs.
Tuesday, August 07, 2012
Of Flies and Men
What 10 000 fruit flies have to tell us about differences between the sexes.
Monday, July 23, 2012
Savira Pharmaceuticals Collaborates with Roche
Joint development of new and innovative drug-candidates to fight influenza.
Monday, June 25, 2012
Blood-clotting Protein Linked to Cancer and Septicaemia
In our not-so-distant evolutionary past, stress often meant imminent danger, and the risk of blood loss, so part of our body’s stress response is to stock-pile blood-clotting factors.
Friday, February 04, 2011
How Cells Export and Embed Proteins in the Membrane
EMBL scientists first to visualise crucial step.
Tuesday, January 04, 2011
Making Enough Red Blood Cells
EMBL scientists identify molecules that ensure red blood cell production
Tuesday, June 01, 2010
Movies for the Human Genome
EMBL scientists identify the genes involved in cell division in humans
Thursday, April 01, 2010
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos